News

A new report today by the Office of Health Economics (OHE) called for a shake up in the way future antibiotics are to be rewarded in Europe so that biopharmaceutical companies can spend more to fight superbugs.

Forthcoming in the Oxford Handbook on the Economics of the Biopharmaceutical Industry, this paper describes the context of the problem of access to medicines in developing countries. The authors detail policies and proposals intended to increase access to both 'global' and 'neglected' diseases, including pricing, compulsory licensing, donations and 'push' and 'pull' mechanisms to stimulate R&D.

In forthcoming chapter in the Oxford Handbook on the Economics of the Biopharmaceutical Industry, experts in the field outline the evolution of cost-effectiveness analysis (CEA) through its use as part of health technology assessment. The authors also explore the theoretical and practical issues that have arisen as the result of using CEA of drugs to make decisions about resource allocation, pricing and use and offer some important recommendations.

Pages